Breaking News! Hainan Implements 20 "Hard-Core" Reforms to Accelerate the Launch of First-Generic Drugs! A Share of Class II Medical Device Registration Certificate Processing Agencies

On April 29th, the Hainan Provincial Information Office held a press conference titled "Interpretation of Hainan's Free Trade Port Policies," primarily introducing the "Implementation Plan for Comprehensively Deepening Regulatory Reforms for Drugs, Medical Devices, and Cosmetics in Hainan to Promote High-Quality Development of the Pharmaceutical Industry." The "Implementation Plan" proposes 20 reform measures in five key areas, aiming to deepen regulatory reforms and meet public demand for high-quality pharmaceutical products. It also aims to vigorously develop Hainan's pharmaceutical, medical device, and cosmetic industries, ensuring greater protection for public health.

The key highlights of the "Implementation Plan for Comprehensively Deepening Regulatory Reforms for Drugs, Medical Devices, and Cosmetics in Hainan to Promote High-Quality Development of the Pharmaceutical Industry" are as follows:

1. "Fast Track" for First-Generic Drugs: Hainan will provide substantial financial support for eligible "first-generic" drugs (the first domestic copy of a foreign drug with expired patents)! Dedicated personnel, comprehensive guidance, and accelerated review and approval processes will ensure rapid market access and access to the general public.

2. Innovation in Review and Approval: Strengthen pre-registration guidance for companies seeking R&D and registration, and improve the review mechanism for innovative products. Continuously enhance clinical research capabilities and increase support for R&D and innovation in traditional Chinese medicine.

3. Quality is paramount: Strengthen standard guidance to promote the quality of generic drugs. Support cross-provincial collaborative supervision and mutual recognition of inspection results, simplify contract manufacturing (especially encouraging strong companies to undertake these projects), formulate management guidelines, and promote consistency evaluation for generic drugs, ensuring better quality and protecting people's lives.

4. New Breakthroughs in Openness:

● Create a benchmark for the application of "real-world research."

● Pilot a new model for staged drug production.

● Promote more convenient imports of pharmaceuticals and medical devices.

● Facilitate the export of high-quality domestic pharmaceuticals, medical devices, and cosmetics.

5. "Lecheng Research and Application + Haikou Production" Accelerates: As the core development zone, the Haikou National High-tech Zone (which contributes nearly 80% of the province's pharmaceutical output value) will fully promote this successful model, enabling innovative overseas pharmaceuticals and medical devices to be quickly manufactured and marketed in Hainan after trial runs in Lecheng. The zone will also deepen its cooperation with Sanya Yazhou Bay Science and Technology City in marine biomedicine and leverage regional collaborations across Guangdong, Hainan, Shanghai, and Hubei to build a stronger industrial chain.

The Haikou High-tech Zone is ambitiously targeting the goal of developing a 100 billion yuan biopharmaceutical industry cluster. It has established a public service platform system covering the entire R&D chain and will leverage global resources to make Hainan the optimal "starting point" and "destination" for innovative pharmaceuticals and medical devices.

In short: Hainan's reforms, from enabling the rapid launch of first-generation generic drugs, improving product quality, expanding market access, to innovating industrial models, are concrete and sincere. They aim to accelerate the delivery of high-quality pharmaceuticals, medical devices, and cosmetics to the public, helping Chinese pharmaceuticals from Hainan reach the world.

To learn more about Hainan's "5 Areas and 20 Reform Measures to Deepen Regulatory Reform of Drugs, Medical Devices, and Cosmetics," please click the link below.

http://www.haikou.gov.cn/zfdt/hkyw/202504/t1423496.shtml

The above is the complete content of Hainan Nayang's editorial introduction to "Breaking News! Hainan's 20 'Hard-Core' Reforms to Accelerate the Launch of First-Generic Drugs! Sharing Information on Class II Medical Device Registration Certificate Processing Agencies." If you are interested in related articles, please continue to follow the official website of Hainan Nayang, a provider of professional Hainan medical device consulting services, Hainan medical device digital therapy CDMO services, Hainan medical device digital therapy CRO consulting services, Hainan medical device clinical trial CRO consulting services, Hainan medical device contract R&D and production CDMO services, and other consulting services.

Medical device registration certificate agency, medical device registration certificate application, Class II medical device registration agency 36.jpg

[Hainan Nayang Biomedical Technology Co., Ltd.]  main services include:

Hainan Class II medical device registration agency, medical device company registration agency, Class II medical device registration certificate agency, Class III medical device registration certificate agency, medical device registration consulting service agency, We provide consultation on registration fees for Class II medical devices, medical device OEM/ODM companies, medical device registration CRO companies, medical device OEM/ODM companies in Hainan, medical device product OEM/ODM companies, Hainan medical device clinical trial CRO consulting service companies, medical device OEM/ODM companies, Hainan medical device CRO services, Hainan medical device CDMO, etc.